UV1 telomerase vaccine with ipilimumab and nivolumab as second line treatment for pleural mesothelioma - A phase II randomised trial.

Autor: Haakensen VD; Dept of Oncology, Oslo University Hospital, Oslo, Norway; Dept of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway; Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway., Öjlert ÅK; Dept of Oncology, Oslo University Hospital, Oslo, Norway; Dept of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway., Thunold S; Dept of Oncology, Oslo University Hospital, Oslo, Norway; Dept of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway., Farooqi S; Dept of Oncology, Oslo University Hospital, Oslo, Norway; Dept of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway., Nowak AK; Medical School of The University of Western Australia, Western Australia, Australia; National Centre for Asbestos-Related Diseases, University of Western Australia, Australia; Sir Charles Gairdner Hospital, Western Australia, Australia., Chin WL; National Centre for Asbestos-Related Diseases, University of Western Australia, Australia; Sir Charles Gairdner Hospital, Western Australia, Australia., Grundberg O; Thoracic Oncology Center, Karolinska University Hospital, Stockholm, Sweden; Dept of Molecular Medicine and Surgery, Karolinska Institute Stockholm, Sweden., Szejniuk WM; Clinical Cancer Research Center & Department of Oncology, Aalborg University Hospital, Aalborg, Denmark; Department of Clinical Medicine, Aalborg University, Aalborg, Denmark., Cedres S; Vall d'Hebron Institute of Oncology, Hospital Universitari Vall d'Hebron, Barcelona, Spain., Sørensen JB; Department of Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark., Dalen TS; Dept of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway., Lund-Iversen M; Dept of Pathology, Oslo University Hospital, Oslo, Norway., Bjaanæs M; Dept of Oncology, Oslo University Hospital, Oslo, Norway., Helland Å; Dept of Oncology, Oslo University Hospital, Oslo, Norway; Dept of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway; Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway. Electronic address: aslaug.helland@medisin.uio.no.

Publikováno v: European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2024 May; Vol. 202, pp. 113973. Date of Electronic Publication: 2024 Mar 01.